For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of Vyndamax and Attruby represents a significant breakthrough . These novel therapies protect the transthyretin protein, preventing its harmful build-up and alleviating the severity of the condition . Patients are now reporting … Read More